Ebateva: Uses, Dosage & Side Effects
A second-generation antihistamine containing ebastine for the treatment of allergic rhinitis and chronic urticaria in adults and adolescents
Ebateva (ebastine) is a prescription second-generation antihistamine used to relieve the symptoms of allergic rhinitis (hay fever) and chronic idiopathic urticaria (hives) in adults and adolescents aged 12 years and older. As an orodispersible tablet that dissolves rapidly on the tongue without the need for water, Ebateva offers a convenient dosage form for patients who have difficulty swallowing conventional tablets. Ebastine works by selectively blocking peripheral histamine H1 receptors, preventing the cascade of allergic symptoms including sneezing, runny nose, itchy eyes, nasal congestion, and skin wheals and itching. It is administered once daily at a dose of 10 mg, providing 24-hour symptom relief with minimal sedation compared to first-generation antihistamines.
Quick Facts: Ebateva
Key Takeaways
- Ebateva contains ebastine 10 mg, a second-generation antihistamine that selectively blocks H1 histamine receptors to relieve allergy symptoms with minimal sedation compared to older antihistamines.
- It is indicated for the symptomatic treatment of allergic rhinitis (seasonal and perennial) and chronic idiopathic urticaria in adults and adolescents aged 12 years and older.
- The orodispersible tablet format dissolves rapidly on the tongue without water, making it especially convenient for patients who have difficulty swallowing or who need to take their medication on the go.
- Ebateva should be used with caution alongside potent CYP3A4 inhibitors (such as ketoconazole or erythromycin) and in patients with known QT prolongation, as elevated ebastine levels may affect cardiac rhythm.
- Once-daily dosing provides sustained 24-hour antihistaminic activity, with symptom relief typically beginning within 1–3 hours of the first dose and full steady-state efficacy achieved within 3–5 days.
What Is Ebateva and What Is It Used For?
Ebateva contains the active substance ebastine, a second-generation, long-acting, selective histamine H1 receptor antagonist belonging to the piperidine class of antihistamines. Unlike first-generation antihistamines such as diphenhydramine (Benadryl) or chlorpheniramine, which readily cross the blood-brain barrier and cause significant sedation, drowsiness, and cognitive impairment, ebastine was specifically designed to act primarily on peripheral H1 receptors with minimal penetration into the central nervous system. This makes it a more suitable choice for patients who need allergy relief while maintaining normal alertness and cognitive function during daily activities including work, school, and driving.
Histamine is one of the key chemical mediators released by mast cells and basophils during an allergic reaction. When an allergic individual is exposed to an allergen (such as pollen, dust mites, pet dander, or mold spores), their immune system recognizes the allergen as a foreign invader and triggers a cascade of events. Immunoglobulin E (IgE) antibodies on the surface of mast cells bind to the allergen, causing the mast cells to degranulate and release stored histamine along with other inflammatory mediators such as leukotrienes, prostaglandins, and cytokines. Histamine then binds to H1 receptors located on smooth muscle cells, endothelial cells, and sensory nerve endings throughout the body, producing the characteristic symptoms of allergic disease.
In the nasal mucosa, histamine binding to H1 receptors causes vasodilation and increased vascular permeability, leading to nasal congestion and rhinorrhea (runny nose). It also stimulates sensory nerve endings, triggering sneezing and nasal itching. In the conjunctiva, H1 receptor activation produces eye itching, tearing, and redness. In the skin, histamine causes vasodilation (erythema), increased vascular permeability (wheals or hives), and stimulation of itch-mediating sensory nerves (pruritus). Ebastine, through its active metabolite carebastine, competitively and reversibly occupies these H1 receptors, blocking histamine from binding and thereby preventing or reducing these allergic symptoms.
Ebastine itself is a prodrug. After oral administration, it undergoes extensive first-pass metabolism in the liver, primarily by the cytochrome P450 enzyme CYP3A4, to form its pharmacologically active metabolite, carebastine. Carebastine is the principal mediator of the antihistaminic effects of ebastine. It has a high affinity for peripheral H1 receptors, a long duration of action (supporting once-daily dosing), and minimal affinity for muscarinic, serotonergic, or adrenergic receptors, which accounts for the low incidence of anticholinergic side effects (such as dry mouth, urinary retention, and constipation) that are commonly associated with first-generation antihistamines.
Ebateva is indicated for the symptomatic treatment of two principal allergic conditions:
- Allergic rhinitis (seasonal and perennial): Seasonal allergic rhinitis (hay fever) is caused by airborne pollens from grasses, trees, and weeds, and typically occurs during specific seasons. Perennial allergic rhinitis is triggered by year-round allergens such as house dust mites, animal dander, mold spores, and cockroach allergens. Ebateva relieves the nasal symptoms (sneezing, rhinorrhea, nasal itching, congestion) as well as the ocular symptoms (itchy, watery, red eyes) associated with both forms of allergic rhinitis. According to the ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines, second-generation antihistamines like ebastine are recommended as first-line pharmacotherapy for mild to moderate allergic rhinitis.
- Chronic idiopathic urticaria: Also known as chronic spontaneous urticaria, this condition is characterized by recurrent wheals (hives), angioedema, or both, occurring for 6 weeks or more without an identifiable external trigger. The EAACI/GA²LEN/EDF/WAO international guidelines recommend second-generation H1 antihistamines as the first-line treatment for chronic urticaria. Ebateva helps reduce the frequency and severity of wheals, reduces associated itching, and improves quality of life for patients with this often debilitating condition.
Clinical studies have demonstrated that ebastine 10 mg once daily is effective in reducing the total symptom score (TSS) in patients with seasonal allergic rhinitis, with statistically significant improvements compared to placebo in sneezing frequency, nasal discharge, nasal obstruction, and eye symptoms. In chronic urticaria trials, ebastine significantly reduced the number and size of wheals, the intensity of pruritus, and overall disease activity compared to placebo. Onset of action is typically observed within 1–3 hours, and antihistaminic activity is maintained for at least 24 hours, supporting convenient once-daily dosing.
The orodispersible tablet formulation of Ebateva is designed to dissolve rapidly on the tongue within seconds, without the need for water. This is particularly beneficial for patients with dysphagia (difficulty swallowing), elderly patients, children aged 12 and older who may have difficulty with conventional tablets, and anyone who needs to take their medication when water is not readily available. The orodispersible formulation has the same bioavailability and efficacy as standard film-coated tablets.
What Should You Know Before Taking Ebateva?
Contraindications
Ebateva should not be used by patients who have a known hypersensitivity (allergy) to ebastine or to any of the excipients contained in the formulation. The excipients in the orodispersible tablet formulation may include gelatin, mannitol, aspartame (a source of phenylalanine), citric acid, mint flavoring, and colloidal silicon dioxide. Patients with phenylketonuria (PKU) should be aware that aspartame is converted to phenylalanine in the body and should consult their doctor before using this product.
Ebateva is also contraindicated in patients with severe hepatic impairment (severe liver disease). Because ebastine is extensively metabolized by the liver (via CYP3A4) to its active metabolite carebastine, patients with severe liver dysfunction may experience significantly elevated plasma levels of the parent drug ebastine. Elevated ebastine concentrations have been associated with a dose-dependent prolongation of the QT interval on the electrocardiogram (ECG), which can increase the risk of potentially serious cardiac arrhythmias, including torsades de pointes.
Warnings and Precautions
At recommended doses, ebastine does not significantly prolong the QT interval. However, at supratherapeutic doses or when plasma levels are elevated due to drug interactions (with CYP3A4 inhibitors) or liver disease, QT prolongation may occur. Use Ebateva with caution if you have a history of QT prolongation, electrolyte imbalances (especially low potassium or magnesium), or heart disease. Do not exceed the recommended dose.
Before starting Ebateva, discuss the following conditions with your healthcare provider:
- Hepatic impairment: Patients with mild to moderate liver disease should use ebastine with caution and under medical supervision. The metabolism of ebastine may be impaired, leading to higher plasma levels. Dose adjustment or alternative treatment may be necessary. Ebateva is contraindicated in severe hepatic impairment.
- Cardiac conditions: Patients with a known history of cardiac arrhythmias, congenital long QT syndrome, uncorrected electrolyte imbalances (hypokalemia, hypomagnesemia), or those taking other medications known to prolong the QT interval should be carefully evaluated before starting ebastine therapy. While ebastine at 10 mg does not meaningfully prolong the QT interval in healthy subjects, the combination of elevated drug levels and pre-existing cardiac risk factors may increase the risk of arrhythmias.
- Renal impairment: No dose adjustment is typically required for patients with mild to moderate kidney disease. The pharmacokinetics of carebastine are not significantly affected by mild to moderate renal impairment. However, patients with severe renal impairment should be monitored, as reduced clearance of carebastine and its metabolites could theoretically occur.
- Elderly patients: Ebastine can generally be used in elderly patients at standard doses. However, elderly patients are more likely to have hepatic or renal impairment, cardiac comorbidities, and concomitant medications, all of which may increase the risk of adverse effects. Clinical monitoring is advisable.
Pregnancy and Breastfeeding
The safety of Ebateva during pregnancy has not been established through adequate, well-controlled clinical studies in pregnant women. Animal reproductive studies with ebastine have not demonstrated teratogenic effects (birth defects) at doses up to several times the maximum recommended human dose. However, animal studies are not always predictive of human response, and as a precaution, Ebateva should not be used during pregnancy unless the expected clinical benefit to the mother clearly outweighs the potential risk to the fetus. If you discover that you are pregnant while taking Ebateva, contact your doctor promptly to discuss whether to continue or discontinue treatment.
It is not fully known whether ebastine or its active metabolite carebastine is excreted in human breast milk. Studies in lactating rats have shown that ebastine and/or its metabolites are distributed into milk. As a precautionary measure, Ebateva should be avoided during breastfeeding unless the benefits of treatment clearly outweigh the potential risks to the nursing infant. If antihistamine therapy is necessary during breastfeeding, discuss the most appropriate treatment option with your healthcare provider, as some second-generation antihistamines (such as cetirizine and loratadine) have more established safety data during lactation.
Children and Adolescents
Ebateva 10 mg orodispersible tablets are approved for use in adolescents aged 12 years and older at the same dose as adults (10 mg once daily). The safety and efficacy of ebastine in children under 12 years of age have not been sufficiently established for this formulation, and Ebateva should not be used in this younger age group. For children aged 6–11 years, lower-dose formulations of ebastine (such as 5 mg tablets or oral solution) may be available in some countries; consult your doctor or pharmacist for age-appropriate alternatives.
Driving and Operating Machinery
Ebastine at the recommended dose of 10 mg has been shown in psychomotor performance studies to have no significant effect on driving ability or the capacity to operate machinery. Unlike first-generation antihistamines, ebastine does not cause clinically relevant sedation or impairment of cognitive or psychomotor function at recommended doses. However, individual responses to medication can vary, and some patients may experience mild drowsiness, particularly at the beginning of treatment. If you feel drowsy or dizzy after taking Ebateva, refrain from driving or operating heavy machinery until you know how the medication affects you. Alcohol may enhance the sedative potential of any antihistamine and should be avoided or limited during treatment.
How Does Ebateva Interact with Other Drugs?
Because ebastine is a prodrug that is extensively metabolized by the cytochrome P450 3A4 (CYP3A4) enzyme system in the liver, its plasma levels and those of its active metabolite carebastine can be significantly affected by other medications that inhibit or induce this enzyme. Understanding these interactions is important for safe and effective use of Ebateva, particularly since elevated plasma concentrations of unmetabolized ebastine have been associated with dose-dependent QT interval prolongation.
The most clinically significant drug interactions with ebastine involve potent CYP3A4 inhibitors. When ebastine is co-administered with these agents, the conversion of ebastine to carebastine is impaired, resulting in elevated plasma levels of the parent compound (ebastine) rather than the active metabolite. While carebastine at therapeutic concentrations does not significantly prolong the QT interval, higher-than-normal concentrations of unmetabolized ebastine may do so. The table below summarizes the most important drug interactions:
| Drug / Substance | Category | Effect | Recommendation |
|---|---|---|---|
| Ketoconazole | Azole antifungal (CYP3A4 inhibitor) | Increases ebastine levels by 2–3 fold; potential QT prolongation | Avoid concomitant use |
| Itraconazole | Azole antifungal (CYP3A4 inhibitor) | Increases ebastine levels; potential QT prolongation | Avoid concomitant use |
| Erythromycin | Macrolide antibiotic (CYP3A4 inhibitor) | Increases ebastine levels; risk of QT prolongation | Avoid or use with caution; monitor ECG |
| Clarithromycin | Macrolide antibiotic (CYP3A4 inhibitor) | May increase ebastine levels | Use with caution |
| Rifampicin | Antitubercular (CYP3A4 inducer) | Decreases ebastine and carebastine levels; reduced efficacy | May need dose adjustment or alternative |
| Grapefruit juice | Food (CYP3A4 inhibitor) | May increase ebastine plasma levels | Avoid large quantities during treatment |
| QT-prolonging drugs | Various (antiarrhythmics, antipsychotics, etc.) | Additive QT prolongation risk if ebastine levels are elevated | Use with caution; clinical and ECG monitoring |
| Alcohol | CNS depressant | May potentiate sedative effects | Avoid or limit alcohol intake |
It is important to note that at the recommended dose of 10 mg, ebastine administered alone does not cause clinically meaningful QT prolongation in healthy volunteers. The concern about QT prolongation arises specifically when plasma levels of unmetabolized ebastine are elevated beyond normal therapeutic ranges due to drug interactions, liver disease, or doses exceeding the recommended amount. Pharmacokinetic studies have shown that co-administration of ketoconazole 400 mg daily with ebastine 20 mg daily resulted in approximately a 2–3 fold increase in ebastine AUC (area under the curve), with corresponding increases in QTc interval of approximately 10–15 milliseconds. While these changes remained below the threshold for clinical concern in healthy subjects, the risk may be amplified in patients with additional cardiac risk factors.
Ebastine does not significantly inhibit or induce major CYP enzymes at therapeutic concentrations, meaning it is unlikely to affect the metabolism of other medications. Co-administration with theophylline, diazepam, cimetidine, or warfarin has not shown clinically significant interactions in pharmacokinetic studies. Nevertheless, you should always inform your doctor, pharmacist, or dentist about all prescription medications, over-the-counter drugs, herbal supplements, and dietary supplements you are taking before starting Ebateva.
If you need to take a short course of an azole antifungal (ketoconazole, itraconazole) or a macrolide antibiotic (erythromycin, clarithromycin), discuss with your doctor whether to temporarily discontinue Ebateva during the course of treatment. Alternative antibiotics (such as amoxicillin) or antifungals (such as fluconazole, which is a weaker CYP3A4 inhibitor) may be considered. Never adjust your medication doses without consulting your healthcare provider first.
What Is the Correct Dosage of Ebateva?
Ebateva should always be used exactly as your doctor or pharmacist has advised. The orodispersible tablet is designed to dissolve rapidly on the tongue within seconds. Simply place the tablet on your tongue, allow it to disintegrate, and swallow with your saliva. No water is needed, although you may take a sip of water afterward if you wish. Do not chew, crush, or swallow the tablet whole before it has dissolved. The tablet can be taken with or without food, as food does not significantly affect the absorption or efficacy of ebastine.
Adults
The standard recommended dose for adults is one Ebateva 10 mg orodispersible tablet taken once daily. Take it at approximately the same time each day to maintain a consistent level of antihistaminic activity. There is no need to increase the dose beyond 10 mg in most patients. In some countries, a 20 mg dose may be available for patients with more severe or refractory symptoms, but this should only be used under explicit medical supervision and is not available in all markets. Do not exceed the dose prescribed by your doctor.
| Patient Group | Dose | Frequency | Notes |
|---|---|---|---|
| Adults (18+ years) | 10 mg | Once daily | Standard dose; dissolve on tongue |
| Adolescents (12–17 years) | 10 mg | Once daily | Same as adult dose |
| Children (<12 years) | Not recommended | — | Use age-appropriate formulations if available |
| Elderly | 10 mg | Once daily | No dose adjustment; monitor for comorbidities |
| Hepatic impairment (mild–moderate) | 10 mg | Once daily | Use with caution; monitor |
| Hepatic impairment (severe) | Contraindicated | — | Do not use |
| Renal impairment | 10 mg | Once daily | No dose adjustment usually needed |
Children and Adolescents
Ebateva 10 mg orodispersible tablets are indicated for adolescents aged 12 years and older at the same dose as adults. For children under 12 years of age, this formulation has not been adequately studied and should not be used. In some countries, lower-strength ebastine formulations (such as 5 mg tablets or oral solution/syrup) are approved for children aged 6–11 years. Parents and caregivers should consult a pediatrician or pharmacist for appropriate pediatric allergy treatment options. The safety and efficacy of ebastine have not been established in children under 6 years of age.
Elderly Patients
No routine dose adjustment is required for elderly patients. The pharmacokinetics of ebastine and carebastine are not significantly altered by age alone. However, elderly patients may be more susceptible to the effects of concurrent medications, hepatic or renal impairment, and cardiac conditions that could influence the safety profile of ebastine. Healthcare providers should consider the overall clinical context, including comorbidities and concomitant medications, when prescribing Ebateva to elderly patients.
Missed Dose
If you forget to take a dose of Ebateva, take it as soon as you remember, unless it is almost time for your next scheduled dose. In that case, skip the missed dose and take your next dose at the usual time. Do not take a double dose to make up for a forgotten one. Taking more than 10 mg in a 24-hour period increases the risk of side effects without providing additional therapeutic benefit. Setting a daily alarm or incorporating medication-taking into a daily routine (such as with breakfast or at bedtime) can help you remember your dose.
Overdose
If you have taken more Ebateva than prescribed, contact your doctor, pharmacist, or local poison control center immediately. In clinical studies and post-marketing experience, overdoses of ebastine have generally been well tolerated. At doses significantly above the recommended 10 mg, the primary concern is QT interval prolongation and the theoretical risk of cardiac arrhythmias. Symptoms of overdose may include drowsiness, headache, dry mouth, nausea, and dizziness. There is no specific antidote for ebastine overdose. Treatment is supportive and symptomatic, including monitoring of vital signs and ECG monitoring for QT prolongation. Activated charcoal may be considered if the overdose occurred within the previous 1–2 hours. Due to the high protein binding of ebastine and carebastine, hemodialysis is not expected to be effective in removing the drug.
How to Take the Orodispersible Tablet
The Ebateva orodispersible tablet is designed for easy and convenient administration:
- Clean, dry hands: Ensure your hands are dry before handling the tablet, as moisture can cause premature disintegration.
- Remove from blister: Peel back the foil backing from the blister pack. Do not push the tablet through the foil, as this may break or crumble the tablet.
- Place on tongue: Immediately place the tablet on your tongue. The tablet will begin to dissolve within seconds.
- Allow to dissolve: Let the tablet dissolve completely on your tongue. Do not chew it or swallow it whole. Swallow with your saliva once dissolved.
- No water needed: You do not need water to take the tablet, although you may drink some if you prefer.
Store any remaining tablets in the original blister packaging to protect them from moisture and light. Do not remove tablets from the blister pack in advance, as exposure to humidity can compromise the integrity of the orodispersible formulation.
What Are the Side Effects of Ebateva?
Like all medicines, Ebateva can cause side effects, although not everyone who takes it will experience them. Ebastine has been extensively studied in clinical trials involving thousands of patients, and its overall safety profile is comparable to other second-generation antihistamines and, in many endpoints, similar to placebo. The majority of side effects reported with ebastine are mild to moderate in severity and transient in nature.
Post-marketing surveillance data collected over more than two decades since ebastine was first approved have been consistent with the clinical trial findings, with no significant new safety signals emerging. The following side effects have been reported:
Common
May affect up to 1 in 10 people
- Headache
- Drowsiness or somnolence
- Dry mouth (xerostomia)
Uncommon
May affect up to 1 in 100 people
- Dizziness
- Fatigue
- Insomnia (difficulty sleeping)
- Nausea
- Abdominal pain
- Nasal dryness (rhinitis sicca)
- Pharyngitis (sore throat)
- Epistaxis (nosebleed)
Rare
May affect up to 1 in 1,000 people
- Palpitations
- Tachycardia (rapid heart rate)
- Skin rash or urticaria (hives)
- Elevated liver enzymes
- Dysmenorrhea (painful menstruation)
Not Known
Frequency cannot be estimated from available data
- Anaphylaxis or severe allergic reactions (extremely rare)
- Angioedema (swelling of face, lips, tongue, or throat)
- QT prolongation (primarily at supratherapeutic doses or with CYP3A4 inhibitors)
- Hepatitis (inflammation of the liver)
Regarding sedation, one of the key advantages of second-generation antihistamines like ebastine is their reduced propensity to cause drowsiness compared to first-generation agents. In controlled clinical trials comparing ebastine 10 mg to placebo, the incidence of somnolence was low and not always significantly different from placebo. However, individual susceptibility varies, and some patients (particularly when initiating treatment) may notice mild drowsiness. This effect tends to diminish with continued use. The ARIA guidelines note that second-generation antihistamines like ebastine are preferred over first-generation agents precisely because of their superior safety profile regarding sedation and cognitive impairment.
Cardiovascular effects, specifically QT interval prolongation, have been a subject of extensive investigation for ebastine. Thorough QT studies (following ICH E14 guidelines) have demonstrated that ebastine at the recommended dose of 10 mg does not cause clinically significant QT prolongation. At 20 mg, the effect on QTc is minimal. However, at suprapharmacologic doses (e.g., 100 mg) or when plasma levels are elevated by CYP3A4 inhibitors, dose-dependent QTc prolongation has been observed. For this reason, the recommended dose should not be exceeded, and concomitant use with potent CYP3A4 inhibitors should be avoided.
The incidence of anticholinergic side effects (dry mouth, blurred vision, constipation, urinary retention) with ebastine is markedly lower than with first-generation antihistamines, reflecting the high selectivity of carebastine for H1 receptors over muscarinic receptors. Dry mouth is the most commonly reported anticholinergic-type side effect, occurring in a small percentage of patients.
Contact your doctor immediately if you experience: palpitations or an irregular heartbeat; fainting or near-fainting episodes; difficulty breathing; swelling of the face, lips, tongue, or throat; or a severe skin rash. These may be signs of a serious allergic reaction or cardiac event that requires immediate medical evaluation. If symptoms are severe, call your local emergency services.
How Should You Store Ebateva?
Proper storage of Ebateva is important to maintain the quality, safety, and efficacy of the medication throughout its shelf life. Orodispersible tablets are particularly sensitive to moisture, as exposure to humidity can cause premature dissolution, softening, or disintegration of the tablet, potentially affecting its dosing accuracy and palatability.
Follow these storage guidelines:
- Temperature: Store at room temperature, not exceeding 25°C (77°F). Avoid exposure to extreme temperatures, including freezing and excessive heat. Do not store in a car glove compartment, near a radiator, or in direct sunlight.
- Moisture protection: Keep the tablets in the original blister packaging until immediately before use. The blister pack provides an important moisture barrier for the orodispersible formulation. Do not transfer tablets to a pill organizer or other container unless they will be used immediately.
- Light protection: Store in the original outer carton when not in use to protect from light exposure.
- Keep out of reach of children: Store Ebateva in a safe location where children cannot access it. The mint flavor and dissolving nature of the orodispersible tablet may make it attractive to young children.
- Expiration date: Do not use Ebateva after the expiry date printed on the blister pack and outer carton. The expiry date refers to the last day of the stated month. Discard any expired medication.
- Disposal: Do not dispose of medications via household waste or wastewater. Return unused or expired medication to your local pharmacy for proper disposal according to local environmental regulations.
When traveling, keep Ebateva in its original packaging and at a stable temperature. If traveling to hot or humid destinations, consider using a sealable plastic bag for additional moisture protection. Airport security screening equipment does not affect the quality of the medication.
What Does Ebateva Contain?
Understanding the composition of your medication is important, especially if you have known allergies, intolerances, or dietary restrictions. Below is a detailed overview of the active and inactive ingredients in Ebateva orodispersible tablets.
Active Ingredient
The active substance is ebastine, 10 mg per orodispersible tablet. Ebastine is a synthetic compound belonging to the piperidine class of antihistamines. Its chemical name is 4-(4-benzhydryloxy-1-piperidyl)-1-(4-tert-butylphenyl)-1-butanone. Ebastine is a prodrug that is metabolized in the liver to its pharmacologically active metabolite, carebastine, which is responsible for the antihistaminic effect.
Inactive Ingredients (Excipients)
| Ingredient | Role | Notes |
|---|---|---|
| Ebastine | Active substance (antihistamine) | 10 mg per tablet |
| Gelatin | Matrix-forming agent | Enables rapid disintegration; derived from animal collagen |
| Mannitol | Sweetener / filler | Provides pleasant taste; sugar-free |
| Aspartame (E951) | Sweetener | Source of phenylalanine; caution in PKU |
| Citric acid | Flavor enhancer / pH adjuster | Provides slightly acidic taste |
| Mint flavor | Flavoring agent | Improves palatability |
| Colloidal silicon dioxide | Glidant / anti-caking agent | Improves manufacturing flow |
Important Notes About Excipients
Aspartame (phenylalanine source): Ebateva orodispersible tablets contain aspartame, which is converted to phenylalanine in the body. This is particularly important for patients with phenylketonuria (PKU), a rare inherited metabolic disorder in which the body cannot properly metabolize phenylalanine. Patients with PKU should consult their doctor before using this product. The amount of phenylalanine per tablet is small, but it must be factored into the daily phenylalanine allowance for PKU patients.
Gelatin: The gelatin used in the orodispersible formulation is typically derived from bovine or porcine collagen. Patients with dietary restrictions (vegetarian, vegan) or religious dietary requirements should be aware of this and discuss alternatives with their pharmacist if necessary.
Appearance and Pack Sizes
Ebateva 10 mg orodispersible tablets are typically white to off-white, round, flat tablets. They may have a mint odor. The tablets are packaged in aluminum foil blister packs to protect against moisture. Common pack sizes include 10, 20, and 30 tablets. Not all pack sizes may be available in every country.
Frequently Asked Questions About Ebateva
Ebateva (ebastine) is a prescription antihistamine used to treat the symptoms of allergic rhinitis (hay fever), including seasonal and perennial forms, as well as chronic idiopathic urticaria (chronic hives). It relieves symptoms such as sneezing, runny nose, nasal itching, nasal congestion, itchy and watery eyes, and skin wheals and itching. It is suitable for adults and adolescents aged 12 years and older.
With dry hands, peel back the foil on the blister pack (do not push the tablet through the foil). Place the tablet on your tongue and let it dissolve, which typically takes just a few seconds. Swallow with your saliva — no water is needed. Do not chew the tablet or swallow it whole before it has dissolved. This formulation is especially convenient when water is not available or for those who have difficulty swallowing conventional tablets.
Ebateva is a second-generation antihistamine specifically designed to cause minimal sedation at recommended doses. In clinical trials, the incidence of drowsiness with ebastine 10 mg was low and often comparable to placebo. However, some individuals may experience mild drowsiness, particularly when first starting treatment. Alcohol may increase this effect. If you feel drowsy, avoid driving or operating machinery until you know how the medication affects you.
Ebateva can generally be used alongside other allergy treatments such as intranasal corticosteroid sprays (e.g., fluticasone, mometasone), nasal saline rinses, and topical eye drops for allergic conjunctivitis. These combination approaches are often recommended in clinical guidelines for moderate to severe allergic rhinitis. However, avoid taking two oral antihistamines at the same time, as this does not provide additional benefit and may increase the risk of side effects. Always consult your doctor before combining medications.
If your allergy symptoms are not adequately controlled after 1–2 weeks of regular daily use, consult your doctor. For allergic rhinitis, adding an intranasal corticosteroid spray may improve symptom control. For chronic urticaria, international guidelines (EAACI/GA²LEN/EDF/WAO) recommend that the dose of the second-generation antihistamine can be increased up to fourfold (under specialist supervision) before considering alternative treatments. Do not adjust your dose without medical advice.
Yes, ebastine has been used safely for long-term treatment of allergic conditions. Patients with perennial allergic rhinitis or chronic urticaria may need to take antihistamines continuously for months or even years. Long-term clinical studies and decades of post-marketing experience have not identified significant safety concerns with prolonged use of ebastine at recommended doses. Regular follow-up with your doctor is recommended to assess ongoing need for treatment and to monitor for any adverse effects.
References
- European Medicines Agency (EMA). Ebastine – Summary of Product Characteristics. Available from national competent authority databases. Last updated 2024.
- Brözek JL, Bousquet J, Agache I, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines – 2023 revision. J Allergy Clin Immunol. 2023;152(4):e1–e30.
- Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734–766.
- British National Formulary (BNF). Ebastine. British Medical Association and Royal Pharmaceutical Society. 2025.
- Mattila MJ, Kuitunen T, Plosila M. Lack of pharmacodynamic and pharmacokinetic interactions between the antihistamine ebastine and ethanol in healthy subjects. Eur J Clin Pharmacol. 1992;43(2):179–184.
- Rico S, Antonijoan RM, Barbanoj MJ. Ebastine in the light of CONGA recommendations for the development of third-generation antihistamines. J Asthma Allergy. 2009;2:73–92.
- Sastre J. Ebastine in allergic rhinitis and chronic idiopathic urticaria. Allergy. 2008;63(Suppl 89):1–20.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List, 2023. Geneva: WHO; 2023.
- De Benedictis FM, de Benedictis D, Canonica GW. New oral H1 antihistamines in children: facts and unmeet needs. Allergy. 2008;63(10):1395–1404.
- Moss AJ, Chaikin P, Garcia JD, et al. A review of the cardiac systemic side-effects of antihistamines: ebastine. Clin Exp Allergy. 1999;29(Suppl 3):200–205.
Editorial Team
Medical Author
iMedic Medical Editorial Team – Specialists in Allergy, Immunology, and Clinical Pharmacology
Medical Reviewer
iMedic Medical Review Board – Independent panel of medical experts following WHO, EMA, and EAACI guidelines
Evidence Standard
GRADE Framework – Level 1A evidence based on systematic reviews and meta-analyses of randomized controlled trials
Editorial Policy
No commercial funding. Independent medical content with no pharmaceutical sponsorship or advertising influence.
This article was last reviewed on . All medical information is based on peer-reviewed sources and international guidelines. Read our editorial standards.